What is Agendia?
Headquartered in Irvine, California, Agendia operates at the intersection of biotechnology and clinical oncology. The company specializes in tumor gene expression profiling, providing physicians with actionable insights to tailor cancer treatments to individual patient profiles. By leveraging a proprietary genomics platform, Agendia has successfully brought four distinct products to market, with a robust pipeline of new diagnostic tools currently under development. Its market position is defined by its commitment to precision medicine, effectively bridging the gap between complex genomic data and clinical decision-making to improve patient outcomes.
How much funding has Agendia raised?
Agendia has raised a total of $179.9M across 6 funding rounds:
Series D
$34M
Series E
$23M
Private Equity
$65M
Other Financing Round
$20.9M
Unspecified
$35M
Debt
$2M
Series D (2007): $34M with participation from Gilde Healthcare, Global Life Science Ventures, and Van Herk Ventures
Series E (2009): $23M led by Van Herk Groep and Gilde Healthcare
Private Equity (2012): $65M supported by Korys, Gilde Healthcare, Breedinvest, ING Corporate Investments, Debiopharm, and Van Herk Ventures
Other Financing Round (2014): $20.9M featuring Norgine
Unspecified (2018): $35M backed by Athyrium Capital Management
Debt (2020): $2M with participation from PPP
Key Investors in Agendia
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros across venture, growth, and private equity strategies, focusing on businesses that enable better care at lower costs.
Van Herk Ventures
A private investment company founded in 1951 based in Rotterdam, providing comprehensive financial and investment management services.
Athyrium Capital Management
A leading investment management platform focused on structured investments, royalties, and equities within the global healthcare sector.
What's next for Agendia?
Looking ahead, Agendia is well-positioned to leverage its historical capital base to accelerate the adoption of its genomic testing suite. The strategic focus remains on expanding the clinical utility of its existing products while fostering deeper integration within the oncology drug development ecosystem. As the personalized medicine landscape matures, Agendia's ability to secure diverse financing—from venture-backed equity to strategic corporate partnerships—provides the necessary liquidity to navigate regulatory hurdles and scale its commercial operations in both domestic and international markets.
See full Agendia company page
